Researchers analyzed the temporal relationship between levels of serum neurofilament light chain and identification of lesions on contrast MRI.
In patients with multiple sclerosis (MS), a high level of serum neurofilament light chain (sNfL) is believed to represent both acute inflammatory activity that disrupts axon integrity and correlation with activity on magnetic resonance imaging (MRI). To evaluate the relationship between sNfL levels and MRI scans, investigators retrospectively analyzed the RESTORE trial, which included monthly MRI and serum samples. The RESTORE investigators randomized stable patients on natalizumab to continue natalizumab or to switch to placebo or other therapy for 24 weeks, before resuming natalizumab in weeks 28 through 52. Both the RESTORE trial and this analysis were industry funded.
Of 166 patients with serum samples for NfL determination (median basel…
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)